Scancell (LON:SCLP - Get Free Report) released its quarterly earnings data on Thursday. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter, Digital Look Earnings reports.
Scancell Stock Performance
Shares of LON:SCLP traded down GBX 0.60 ($0.01) on Friday, reaching GBX 9.40 ($0.12). The company's stock had a trading volume of 530,760 shares, compared to its average volume of 1,511,060. The stock has a market capitalization of £87.38 million, a P/E ratio of -940.00 and a beta of 0.35. Scancell has a 52-week low of GBX 8.60 ($0.11) and a 52-week high of GBX 19.75 ($0.24). The stock's 50-day moving average is GBX 10.84 and its two-hundred day moving average is GBX 13.63. The company has a debt-to-equity ratio of 61.41, a current ratio of 3.42 and a quick ratio of 13.01.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
See Also
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
